Kacie M Brown, | |
1113 Korina Ave Unit A, Grand Forks Afb, ND 58204-1378 | |
(614) 499-7950 | |
Not Available |
Full Name | Kacie M Brown |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 1113 Korina Ave Unit A, Grand Forks Afb, North Dakota |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174895833 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kacie M Brown, 1113 Korina Ave Unit A, Grand Forks Afb, ND 58204-1378 Ph: (614) 499-7950 | Kacie M Brown, 1113 Korina Ave Unit A, Grand Forks Afb, ND 58204-1378 Ph: (614) 499-7950 |
News Archive
Physicians treating patients who have suffered tympanic membrane perforation as a result of blast should also look for signs of comcomitant brain or neurologic injury, according to a study published in the August 23 edition of the New England Journal of Medicine .
A team of international researchers led by Northwestern Medicine scientists has identified how a defective protein plays a central role in a rare, lethal childhood disease known as Giant Axonal Neuropathy, or GAN.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
› Verified 8 days ago
Michael Klose, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1599 J St, Grand Forks Afb, ND 58205 Phone: 701-747-5601 | |
Breezetta Lowanet Etienne, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1599 J St, Grand Forks Afb, ND 58205 Phone: 701-747-6687 |